Clostridioides difficile Infections During the COVID-19 Pandemic

To compare rates of prepandemic Clostridioides difficile infection (CDI) during the COVID-19 pandemic and the rates of antibacterial use prepandemic and during the COVID-19 pandemic. This was a retrospective data review. This study was performed at an academic medical center. Patients were all adult patients admitted to the hospital between April 1, 2019, and December 31, 2019, who were tested for CDI and admitted in the same time frame in 2020, and who were tested for CDI were included in the study. Retrospective data analysis was conducted across 5 hospitals from April 1 to December 31, 2019 (prepandemic), and on the same dates in 2020 during the pandemic. The standardized infection ratio (SIR) for hospital-acquired CDI (HA-CDI) was calculated for both groups. The mean and normal distributions were calculated for all values in both the groups. The 2 groups were compared using unpaired t tests for continuous variables and χ 2 tests for discrete variables. Thirty-six patients were diagnosed with HA-CDI before the pandemic (2019), and 45 patients during the pandemic (2020). The 2019 HA-CDI SIRs were 0.47 in 2019 and 0.56 in 2020. Days of therapy per 1000 patient-days of antibiotics increased from 337.1 to 364.6 (P = 0.0057). Analysis of 153 inpatients with diarrhea revealed no positive association between COVID and CDI. During the COVID-19 pandemic, empiric broad-spectrum antibacterial use increased in our system, as did HA-CDI SIR compared with the national standards. We did not observe a positive correlation between COVID-19 and CDI.

• Publication year

  2023

• Venue

  Infectious Diseases in Clinical Practice

• Publication date

  2023-07-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1097/ipc.0000000000001273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19

  2022cited by this paper
• The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network

  2021cited by this paper
• Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

  2020cited by this paper
• Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

  2020cited by this paper
• Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection

  2020cited by this paper
• Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection

  2020cited by this paper
• Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study

  2016cited by this paper
• Performance management of Clostridium difficile infection in hospitals - The carrot or stick approach?

  2016cited by this paper
• Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use.

  2014cited by this paper
• Clostridium difficile spore biology: sporulation, germination, and spore structural proteins.

  2014cited by this paper
• European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

  2009cited by this paper
• Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis.

  1981cited by this paper

• No citing papers are available for this paper.